Last updated on July 2018

Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis


Brief description of study

This is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of E6007 once daily for 8 weeks in Japanese participants with moderate active ulcerative colitis. Participants will be stratified by prior therapeutic treatment and Mayo score at Baseline, and will be randomized 1:1:1 to receive E6007 30 milligrams (mg), E6007 60 mg or placebo.

Clinical Study Identifier: NCT03018054

Contact Investigators or Research Sites near you

Start Over

Public Relations Group

EA Pharma Trial Site #1
Shimotsuga, Japan
1.85miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.